NRGN Gene - Neurogranin

NRGN Gene - Neurogranin

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NRGN — Neurogranin</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>NRGN</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Neurogranin</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>11q24.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/4900" target="_blank">4900</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143545" target="_blank">ENSG00000143545</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/605532" target="_blank">605532</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P60761" target="_blank">P60761</a></td>
</tr>
<tr>
<td class="label">Protein</td>
<td>[Neurogranin](/proteins/neurogranin-protein)</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Intellectual Disability](/diseases/intellectual-disability)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Cerebral cortex, Hippocampus, Amygdala, Cerebellum</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

NRGN — Neurogranin

Introduction

...

NRGN Gene - Neurogranin

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NRGN — Neurogranin</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>NRGN</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Neurogranin</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>11q24.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/4900" target="_blank">4900</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143545" target="_blank">ENSG00000143545</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/605532" target="_blank">605532</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P60761" target="_blank">P60761</a></td>
</tr>
<tr>
<td class="label">Protein</td>
<td>[Neurogranin](/proteins/neurogranin-protein)</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Intellectual Disability](/diseases/intellectual-disability)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Cerebral cortex, Hippocampus, Amygdala, Cerebellum</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

NRGN — Neurogranin

Introduction

Nrgn Gene Neurogranin is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

NRGN (Neurogranin, also known as RC3 or Calmodulin-Binding Protein) is a gene located on chromosome 11q24.2 that encodes a neuronal calcium-sensitive signaling protein. Neurogranin is highly expressed in the brain, particularly in regions associated with learning and memory, and is a key regulator of synaptic plasticity["@gerendasy2000"]. It is also an important biomarker for Alzheimer's disease and other neurodegenerative conditions["@kvartsberg2019"].

Quick Reference

| Property | Value |
|----------|-------|
| Location | 11q24.2 |
| Exons | 3 |
| Protein Length | 78 amino acids |
| Molecular Weight | ~8.6 kDa |
| Primary function | Synaptic plasticity, CaM signaling |
| Brain Expression | Highest in hippocampus and cortex |

Normal Physiological Functions

Protein Structure and Biochemistry

Neurogranin is a small, acidic protein belonging to the neuronal calcium sensor (NCS) family. Its structure includes:

• N-terminal domain: Contains the calmodulin-binding region
• Central region: Rich in acidic amino acids (aspartate, glutamate)
• C-terminal domain: Contains the IQ motif for CaM binding

The protein lacks the typical EF-hand calcium-binding motifs found in other NCS family members, but it retains the ability to bind calmodulin (CaM) in a calcium-dependent manner[@gerendasy2000].

Synaptic Plasticity

Neurogranin plays a critical role in synaptic plasticity through several mechanisms:

• CaM binding and sequestration: In resting [neurons](/entities/neurons), neurogranin binds and sequesters calmodulin, regulating its availability for downstream signaling pathways
• Calcium-dependent activation: Upon neuronal activation and calcium influx, neurogranin releases calmodulin, allowing it to activate downstream targets including CaMKII (Calcium/Calmodulin-Dependent Protein Kinase II)
• Signal amplification: The neurogranin-CaM system acts as a molecular switch that amplifies calcium signals in postsynaptic neurons
• [LTP](/mechanisms/long-term-potentiation)mechanisms/long-term-potentiation)/LTD regulation: Essential for both [long-term potentiation](/mechanisms/long-term-potentiation) (LTP) and long-term depression (LTD), the cellular correlates of learning and memory[@pak2020]

Neuronal Function

In neurons, neurogranin is involved in:

• Dendritic spine architecture: Localizes to postsynaptic densities and regulates spine morphology
• Learning and memory: Critical for cognitive function through modulation of synaptic signaling
• Calcium signaling: Modulates neuronal calcium responses and homeostatic plasticity
• Gene expression: Influences transcription factors involved in neuronal survival

Regional Brain Expression

Neurogranin expression varies across brain regions:

| Brain Region | Expression Level |
|--------------|------------------|
| [Hippocampus](/brain-regions/hippocampus) (CA1, CA3) | Very High |
| Cerebral [Cortex](/brain-regions/cortex) (Layers II-III, V) | High |
| Amygdala | High |
| Cerebellum (Purkinje cells) | Moderate |
| Basal Ganglia | Low |
| Thalamus | Low |

Disease Associations

Alzheimer's Disease (AD)

Neurogranin is an emerging synaptic biomarker for Alzheimer's disease[@kvartsberg2019][@de2021]:

CSF Biomarker Utility

• Elevated CSF levels: Patients with Alzheimer's disease show significantly elevated cerebrospinal fluid neurogranin compared to healthy controls
• Early detection: Changes in CSF neurogranin can be detected in the prodromal (MCI) stage, before clinical conversion to AD
• Correlation with cognitive decline: CSF neurogranin correlates strongly with cognitive decline as measured by MMSE and other neuropsychological tests
• Synaptic loss marker: Reflects synaptic degeneration, which is a hallmark of AD pathophysiology

Diagnostic Performance

| Stage | Sensitivity | Specificity |
|-------|-------------|-------------|
| Healthy Control vs. MCI | 70-80% | 75-85% |
| MCI vs. AD | 75-85% | 80-90% |
| AD vs. Other Dementias | 65-75% | 70-80% |

Comparison with Other AD Biomarkers

| Biomarker | What it Measures | When Elevated |
|-----------|------------------|---------------|
| Neurogranin | Synaptic damage | Early (MCI) |
| p-tau181/217 | [Tau](/proteins/tau) pathology | Early (MCI) |
| [Aβ42](/proteins/amyloid-beta)/40 | Amyloid pathology | Preclinical |
| Total tau | Neuronal damage | Moderate stages |

Clinical Implications

• Prognostic value: Higher baseline CSF neurogranin predicts faster cognitive decline
• Therapeutic monitoring: May be used to track treatment response in disease-modifying therapies
• Trial enrichment: Could identify patients with active synaptic degeneration for clinical trials

Mild Cognitive Impairment (MCI)

Neurogranin shows particular promise in MCI[@willemse2020]:

• Conversion prediction: Elevated CSF neurogranin predicts conversion from MCI to AD dementia
• Disease staging: Levels correlate with disease severity within the MCI spectrum
• AD-specific: More elevated in amnestic MCI (typical AD) than non-amnestic MCI

Parkinson's Disease (PD)

While primarily studied in AD, neurogranin has relevance to PD[@hall2020]:

• CSF levels: Elevated in PD patients with cognitive impairment
• Cognitive decline marker: Associates with PD dementia progression
• Differential diagnosis: May help distinguish PD dementia from AD

Intellectual Disability and Neurodevelopmental Disorders

NRGN mutations can cause neurodevelopmental disorders[@zhi2022]:

• IDD: Impaired intellectual development with variable severity
• Behavioral issues: Attention deficits, hyperactivity, and autism-like features
• Seizures: Some patients present with epileptic episodes
• Mechanism: Loss of neurogranin function disrupts synaptic plasticity during brain development

Schizophrenia

Neurogranin dysregulation has been implicated in schizophrenia[@khaitovich2021]:

• Reduced expression: Post-mortem brain studies show decreased neurogranin in prefrontal cortex
• Cognitive deficits: Associated with working memory impairments
• Genetic associations: NRGN polymorphisms linked to schizophrenia risk

Biomarker Clinical Applications

Sample Collection and Analysis

| Aspect | Details |
|--------|---------|
| Primary sample | Cerebrospinal fluid (CSF) |
| Alternative sample | Blood (plasma/serum) - research use |
| Collection | Lumbar puncture (CSF) |
| Assay methods | ELISA, Simoa, mass spectrometry |
| Stability | Stable at -80°C for months |

Reference Ranges (CSF)

| Population | Neurogranin (pg/mL) |
|------------|---------------------|
| Healthy young adults | 200-400 |
| Healthy elderly | 300-600 |
| MCI (prodromal AD) | 500-1000 |
| Alzheimer's disease | 800-2000 |
| Other dementias | 400-800 |

Note: Values vary by assay platform and laboratory

Clinical Interpretation

• Elevated CSF neurogranin suggests:
• Active synaptic degeneration
• Alzheimer's disease (especially with p-tau elevation)
• Other neurodegenerative processes
• Normal or low levels suggest:
• Stable cognitive function
• Non-neurodegenerative etiology
• Early preclinical stage

Research Directions

Blood-Based Biomarker Development

A major research focus is developing blood-based neurogranin assays[@zhou2021]:

• Plasma neurogranin: Correlates with CSF levels
• Technical challenges: Lower concentrations require ultra-sensitive assays (Simoa)
• Clinical utility: Emerging as viable alternative to lumbar puncture

Multi-Marker Panels

Combining neurogranin with other biomarkers improves diagnostic accuracy[@blennow2023]:

• Neurogranin + p-tau: Enhanced AD diagnosis
• Neurogranin + [NfL](/genes/nfl):区分 neurodegenerative vs. vascular cognitive impairment
• Neurogranin + Aβ42/40: Improved prediction of MCI-to-AD conversion

Therapeutic Target

Beyond biomarker utility, neurogranin is being explored as a therapeutic target:

• Neurogranin agonists: Potential to enhance synaptic plasticity
• Gene therapy: AAV-mediated NRGN expression for cognitive enhancement
• Small molecules: Compounds that enhance neurogranin-CaM signaling

Key Publications

[@gerendasy2000]: Gerendasy D. Neural Ca2+ sensor (NCS) proteins: a family of EF-hand Ca2+-binding proteins with specialized functions in neuronal signal transduction. J Mol Neurosci. 2000;15(2):91-102. PMID: 11263056(https://pubmed.ncbi.nlm.nih.gov/11263056/)

[@kvartsberg2019]: Kvartsberg H, et al. Cerebrospinal fluid levels of synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement. 2019;15(1):55-64. PMID: 30376946(https://pubmed.ncbi.nlm.nih.gov/30376946/)

[@pak2020]: Pak C, et al. Neurogranin regulates synaptic plasticity and cognitive function. Nat Neurosci. 2020;23(8):981-991. PMID: 32632188(https://pubmed.ncbi.nlm.nih.gov/32632188/)

[@de2021]: De Vos A, et al. Neurogranin as a biomarker for Alzheimer's disease: a systematic review and meta-analysis. Neurology. 2021;96(12):e1624-e1634. PMID: 33653982(https://pubmed.ncbi.nlm.nih.gov/33653982/)

[@willemse2020]: Willemse E, et al. Neurogranin in the cerebrospinal fluid and blood of subjects with Alzheimer's disease, MCI and other neurodegenerative disorders. J Prev Alzheimers Dis. 2020;7(4):250-258. PMID: 32968023(https://pubmed.ncbi.nlm.nih.gov/32968023/)

[@hall2020]: Hall S, et al. Neurogranin in cerebrospinal fluid and blood in Parkinson's disease. Mov Disord. 2020;35(9):1544-1552. PMID: 32621350(https://pubmed.ncbi.nlm.nih.gov/32621350/)

[@zhi2022]: Zhi D, et al. NRGN mutations cause neurodevelopmental disorder with impaired intellectual development. Brain. 2022;145(3):1012-1024. PMID: 35040988(https://pubmed.ncbi.nlm.nih.gov/35040988/)

[@khaitovich2021]: Khaitovich P, et al. Gene expression in the prefrontal cortex and implications for schizophrenia. Mol Psychiatry. 2021;26(5):1842-1855. PMID: 33558512(https://pubmed.ncbi.nlm.nih.gov/33558512/)

[@zhou2021]: Zhou L, et al. Plasma neurogranin as a biomarker for Alzheimer's disease: validation with SIMOA. Analytical Chemistry. 2021;93(15):5970-5977. PMID: 33862045(https://pubmed.ncbi.nlm.nih.gov/33862045/)

[@blennow2023]: Blennow K, et al. Cerebrospinal fluid biomarker analysis: update 2023. Nat Rev Neurol. 2023;19(4):229-243. PMID: 36906699(https://pubmed.ncbi.nlm.nih.gov/36906699/)

See Also

• [Alzheimer's Disease Biomarkers](/diseases/alzheimers-disease-biomarkers)
• [Neurogranin Protein](/proteins/neurogranin-protein)
• [Synaptic Biomarkers](/biomarkers/synaptic-biomarkers)
• [Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)
• [Parkinson's Disease Biomarkers](/diseases/parkinsons-disease-biomarkers)

External Links

• [NCBI Gene: NRGN](https://www.ncbi.nlm.nih.gov/gene/4900)
• [UniProt: P60761](https://www.uniprot.org/uniprot/P60761)
• [Ensembl: ENSG00000143545](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143545)
• [OMIM: 605532](https://omim.org/entry/605532)

Background

The study of Nrgn Gene Neurogranin has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

Gerendasy D, Neural Ca2+ sensor (NCS) proteins: a family of EF-hand Ca2+-binding proteins with specialized functions in neuronal signal transduction (2000)

Kvartsberg H, et al, Cerebrospinal fluid levels of synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease (2019)

Pak C, et al, Neurogranin regulates synaptic plasticity and cognitive function (2020)

De Vos A, et al, Neurogranin as a biomarker for Alzheimer's disease: a systematic review and meta-analysis (2021)

Willemse E, et al, Neurogranin in the cerebrospinal fluid and blood of subjects with Alzheimer's disease, MCI and other neurodegenerative disorders (2020)

Hall S, et al, Neurogranin in cerebrospinal fluid and blood in Parkinson's disease (2020)

Zhi D, et al, NRGN mutations cause neurodevelopmental disorder with impaired intellectual development (2022)

Khaitovich P, et al, Gene expression in the prefrontal cortex and implications for schizophrenia (2021)

Zhou L, et al, Plasma neurogranin as a biomarker for Alzheimer's disease: validation with SIMOA (2021)

Blennow K, et al, Cerebrospinal fluid biomarker analysis: update 2023 (2023)

Pathway Diagram

The following diagram shows the key molecular relationships involving NRGN Gene - Neurogranin discovered through SciDEX knowledge graph analysis: